Innate Pharma Files 6-K Report

Ticker: IPHYF · Form: 6-K · Filed: May 13, 2025 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory-update

TL;DR

Innate Pharma filed a 6-K on 5/13/25, incorporating an exhibit into its SEC filings.

AI Summary

Innate Pharma S.A. filed a Form 6-K on May 13, 2025, reporting information as a foreign private issuer. The filing includes a reference to Exhibit 99.1, which is incorporated by reference into the company's registration statements. The company is based in Marseille, France, and its fiscal year ends on December 31.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Innate Pharma's status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing by a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

  • Innate Pharma S.A. (company) — Registrant
  • May 13, 2025 (date) — Filing Date
  • Marseille, France (location) — Company Headquarters
  • 001-39084 (other) — Commission File Number

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It is used to furnish information that the issuer makes or is required to make public pursuant to the laws of its home country, or that is required to be filed with or made public by any stock exchange on which its securities are traded.

When was this Form 6-K filed?

This Form 6-K was filed on May 13, 2025.

Where is Innate Pharma S.A. headquartered?

Innate Pharma S.A. is headquartered in Marseille, France.

What is the Commission File Number for Innate Pharma S.A.?

The Commission File Number for Innate Pharma S.A. is 001-39084.

What does the filing indicate about Exhibit 99.1?

The filing states that Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registrant's registration statements.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 13, 2025 regarding Innate Pharma SA (IPHYF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.